BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 41 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $169,702 | +105963.8% | 84,851 | +32.4% | 0.00% | – |
| Q1 2023 | $160 | +240.4% | 64,079 | +123.3% | 0.00% | – |
| Q4 2022 | $47 | -100.0% | 28,700 | -50.8% | 0.00% | – |
| Q3 2022 | $243,000 | +556.8% | 58,300 | +430.0% | 0.00% | – |
| Q1 2022 | $37,000 | -74.3% | 11,000 | -71.6% | 0.00% | – |
| Q1 2021 | $144,000 | -62.5% | 38,700 | -53.3% | 0.00% | – |
| Q4 2020 | $384,000 | +114.5% | 82,860 | +98.5% | 0.00% | – |
| Q4 2019 | $179,000 | -33.9% | 41,744 | -40.3% | 0.00% | – |
| Q3 2019 | $271,000 | -34.1% | 69,939 | -32.7% | 0.00% | -100.0% |
| Q2 2019 | $411,000 | +115.2% | 103,878 | +136.2% | 0.00% | – |
| Q1 2019 | $191,000 | +334.1% | 43,974 | +307.2% | 0.00% | – |
| Q3 2017 | $44,000 | – | 10,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Weaver Consulting Group | 130,000 | $437,000 | 0.21% |
| Ikarian Capital, LLC | 304,161 | $1,022,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 265,000 | $890,000 | 0.12% |
| S.C. Financial Services, Inc. | 15,285 | $51,000 | 0.06% |
| JMAC ENTERPRISES LLC | 45,430 | $153,000 | 0.04% |
| CFO4Life Group, LLC | 12,000 | $40,000 | 0.01% |
| OSAIC HOLDINGS, INC. | 10,839 | $1,329,000 | 0.00% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $10,000 | 0.00% |
| BOOTHBAY FUND MANAGEMENT, LLC | 29,186 | $98,000 | 0.00% |
| RAYMOND JAMES & ASSOCIATES | 190,403 | $640,000 | 0.00% |